vs
Side-by-side financial comparison of FGI Industries Ltd. (FGI) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $30.5M, roughly 1.1× FGI Industries Ltd.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs -14.4%). ZEVRA THERAPEUTICS, INC. produced more free cash flow last quarter ($5.5M vs $2.3M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs -0.5%).
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
FGI vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.5M | $34.1M |
| Net Profit | $-2.6M | — |
| Gross Margin | 26.7% | — |
| Operating Margin | -2.2% | 27.3% |
| Net Margin | -8.6% | — |
| Revenue YoY | -14.4% | 183.4% |
| Net Profit YoY | -553.1% | — |
| EPS (diluted) | $-1.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.5M | $34.1M | ||
| Q3 25 | $35.8M | $26.1M | ||
| Q2 25 | $31.0M | $25.9M | ||
| Q1 25 | $33.2M | $20.4M | ||
| Q4 24 | $35.6M | $12.0M | ||
| Q3 24 | $36.1M | $3.7M | ||
| Q2 24 | $29.4M | $4.4M | ||
| Q1 24 | $30.8M | $3.4M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-1.7M | $-544.0K | ||
| Q2 25 | $-1.2M | $74.7M | ||
| Q1 25 | $-629.1K | $-3.1M | ||
| Q4 24 | $-402.3K | — | ||
| Q3 24 | $-550.1K | $-33.2M | ||
| Q2 24 | $163.6K | $-19.9M | ||
| Q1 24 | $-412.2K | $-16.6M |
| Q4 25 | 26.7% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 26.8% | — | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 30.5% | — | ||
| Q1 24 | 27.4% | — |
| Q4 25 | -2.2% | 27.3% | ||
| Q3 25 | 1.0% | 15.9% | ||
| Q2 25 | -2.7% | -274.5% | ||
| Q1 25 | -3.9% | -26.3% | ||
| Q4 24 | -3.5% | -128.0% | ||
| Q3 24 | -0.2% | -739.0% | ||
| Q2 24 | -1.5% | -534.8% | ||
| Q1 24 | -1.0% | -598.1% |
| Q4 25 | -8.6% | — | ||
| Q3 25 | -4.6% | -2.1% | ||
| Q2 25 | -4.0% | 288.7% | ||
| Q1 25 | -1.9% | -15.2% | ||
| Q4 24 | -1.1% | — | ||
| Q3 24 | -1.5% | -899.2% | ||
| Q2 24 | 0.6% | -447.9% | ||
| Q1 24 | -1.3% | -485.3% |
| Q4 25 | $-1.63 | — | ||
| Q3 25 | $-0.86 | $-0.01 | ||
| Q2 25 | $-0.64 | $1.21 | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $-0.38 | — | ||
| Q3 24 | $-0.29 | $-0.69 | ||
| Q2 24 | $0.08 | $-0.48 | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $17.3M | $154.7M |
| Total Assets | $69.5M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $62.4M | ||
| Q3 25 | $1.9M | $54.4M | ||
| Q2 25 | $2.5M | $47.7M | ||
| Q1 25 | $1.2M | $37.3M | ||
| Q4 24 | $4.6M | $33.8M | ||
| Q3 24 | $3.0M | $54.0M | ||
| Q2 24 | $1.3M | $39.3M | ||
| Q1 24 | $3.3M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $17.3M | $154.7M | ||
| Q3 25 | $19.7M | $133.2M | ||
| Q2 25 | $21.3M | $117.2M | ||
| Q1 25 | $21.8M | $41.0M | ||
| Q4 24 | $22.3M | $39.7M | ||
| Q3 24 | $23.5M | $69.8M | ||
| Q2 24 | $23.8M | $32.5M | ||
| Q1 24 | $23.9M | $48.8M |
| Q4 25 | $69.5M | $284.7M | ||
| Q3 25 | $73.0M | $270.1M | ||
| Q2 25 | $71.7M | $256.3M | ||
| Q1 25 | $68.5M | $172.7M | ||
| Q4 24 | $75.5M | $178.1M | ||
| Q3 24 | $74.7M | $191.6M | ||
| Q2 24 | $69.9M | $144.4M | ||
| Q1 24 | $68.6M | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $5.5M |
| Free Cash FlowOCF − Capex | $2.3M | $5.5M |
| FCF MarginFCF / Revenue | 7.5% | 16.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.5K | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $5.5M | ||
| Q3 25 | $-1.9M | $4.7M | ||
| Q2 25 | $7.6M | $-3.6M | ||
| Q1 25 | $-7.4M | $-8.2M | ||
| Q4 24 | $617.4K | $-16.3M | ||
| Q3 24 | $-915.0K | $-18.1M | ||
| Q2 24 | $862.1K | $-19.1M | ||
| Q1 24 | $-8.0M | $-16.2M |
| Q4 25 | $2.3M | $5.5M | ||
| Q3 25 | $-2.1M | $4.2M | ||
| Q2 25 | $7.4M | $-3.8M | ||
| Q1 25 | $-7.7M | $-8.3M | ||
| Q4 24 | $-214.1K | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $281.5K | — | ||
| Q1 24 | $-8.6M | — |
| Q4 25 | 7.5% | 16.1% | ||
| Q3 25 | -5.9% | 15.9% | ||
| Q2 25 | 23.8% | -14.7% | ||
| Q1 25 | -23.3% | -40.8% | ||
| Q4 24 | -0.6% | — | ||
| Q3 24 | -3.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -28.0% | — |
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.7% | 2.1% | ||
| Q2 25 | 0.7% | 0.8% | ||
| Q1 25 | 1.1% | 0.5% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 2.0% | 0.0% | ||
| Q1 24 | 2.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
